FDA Inspection 1066575 — Taro Pharmaceuticals U.S.A., Inc.
The FDA completed an inspection of Taro Pharmaceuticals U.S.A., Inc. on Aug 27, 2018 in Hawthorne, NY. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI)
- End Date
- Aug 27, 2018
- Fiscal Year
- 2018
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Hawthorne, NY (United States)
Additional Details
Postmarket Adverse Drug Experience (PADE)